nach oben

Irish Journal of Medical Science (1971 -)

01.04.2024 | Original Article

The effect of indicators of CALLY index on survival in glioblastoma

verfasst von: Umut Ogün Mutlucan, Cihan Bedel, Fatih Selvi, Ökkeş Zortuk, Cezmi Çağrı Türk, Mustafa Korkut

Erschienen in: Irish Journal of Medical Science (1971 -)

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glioblastoma is the most common primary brain tumor in adults. Recently, research has been published on the potential prognostic indicators associated with different types of cancer. Due to the limited availability of data investigating the relationship between the CALLY index and glioblastoma patients, we aimed to conduct this study.

Materials and methods

Between January 2017 and December 2023, we conducted a study on patients diagnosed with glioblastoma. We collected demographic data and routine laboratory tests at the time of admission. To calculate the CALLY index, we used the formula (albumin value × lymphocyte count) / CRP value × 104. Parameters were compared for in-hospital mortality across different groups.

Results

The study analyzed 202 patients who met the inclusion criteria. Of these, 165 (81.7%) were classified as “survivors” and 37 (18.3%) as “deceased.” A comparison of hematologic parameters between the two groups showed a significantly lower CALLY index in the “deceased” group (3.05 (4.92)) compared to the “survivor” group (10.13 (13.69)) (p < 0.001). The study compared the parameters between groups with regard to in-hospital mortality.

Conclusions

Based on the results of the study, we conclude that the CALLY index can be considered an easily applicable indicator for the mortality of glioblastoma patients.

Mermut O, Inanc B (2020) The effect of indicators of systemic inflammatory response on survival in glioblastoma multiforme. Turk Neurosurg 30(5):658–665. https://doi.org/10.5137/1019-5149.JTN.27068-19.1CrossRefPubMed

Bambury RM, Teo MY, Power DG et al (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114(1):149–154. https://doi.org/10.1007/s11060-013-1164-9CrossRefPubMed

Jarmuzek P, Kozlowska K, Defort P et al (2023) Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 15(13):3339. https://doi.org/10.3390/cancers15133339CrossRefPubMed

Tan AC, Ashley DM, López GY et al (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70(4):299–312. https://doi.org/10.3322/caac.21613CrossRefPubMed

Weng W, Chen X, Gong S et al (2018) Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res 40(11):917–922. https://doi.org/10.1080/01616412.2018.1497271CrossRefPubMed

Ji F, Fu S, Guo Z et al (2016) Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget 7(44):72276–72289. https://doi.org/10.18632/oncotarget.10848CrossRefPubMedPubMedCentral

Förnvik K, Maddahi A, Liljedahl E et al (2021) What is the role of CRP in glioblastoma? Cancer Treat Res Commun 26:100293. https://doi.org/10.1016/j.ctarc.2020.100293CrossRefPubMed

Topkan E, Kucuk A, Ozdemir Y et al (2020) Systemic inflammation response index predicts survival outcomes in glioblastoma multiforme patients treated with standard Stupp protocol. J Immunol Res 2020:8628540. https://doi.org/10.1155/2020/8628540CrossRefPubMedPubMedCentral

Yang C, Hu BW, Tang F et al (2022) Prognostic value of Systemic Immune-Inflammation Index (SII) in patients with glioblastoma: a comprehensive study based on meta-analysis and retrospective single-center analysis. J Clin Med 11(24):7514. https://doi.org/10.3390/jcm11247514CrossRefPubMedPubMedCentral

10.

Chen N, Peng C, Li D (2022) Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma. Front Immunol 13:869307. https://doi.org/10.3389/fimmu.2022.869307CrossRefPubMedPubMedCentral

11.

Massara M, Persico P, Bonavita O et al (2017) Neutrophils in glioma. Front Immunol 8:1349. https://doi.org/10.3389/fimmu.2017.01349CrossRefPubMedPubMedCentral

12.

Zhou Y, Xiao D, Jiang X, Nie C (2023) EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma. J Transl Med 21(1):28. https://doi.org/10.1186/s12967-023-03883-4CrossRefPubMedPubMedCentral

13.

Chen J, Wang H, Deng C, Fei M (2023) SLC12A5 as a novel potential biomarker of glioblastoma multiforme. Mol Biol Rep 50(5):4285–4299. https://doi.org/10.1007/s11033-023-08371-yCrossRefPubMed

14.

Litak J, Mazurek M, Grochowski C et al (2019) PD-L1/PD-1 Axis in glioblastoma multiforme. Int J Mol Sci 20(21):5347. https://doi.org/10.3390/ijms20215347CrossRefPubMedPubMedCentral

15.

Yang M, Lin SQ, Liu XY et al (2023) Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: from the investigation on nutrition status and clinical outcome of common cancers study. Front Immunol 14:1131496. https://doi.org/10.3389/fimmu.2023.1131496CrossRefPubMedPubMedCentral

16.

Lida H, Tani M, Komeda K et al (2022) Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB (Oxford) 24(1):101–115. https://doi.org/10.1016/j.hpb.2021.06.414CrossRef

17.

Witthayanuwat S, Pesee M, Supaadirek C et al (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19(9):2613–2617. https://doi.org/10.22034/APJCP.2018.19.9.2613CrossRefPubMedPubMedCentral

18.

Shi X, Li H, Xu Y et al (2022) The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients. Neurol Sci 43(9):5523–5531. https://doi.org/10.1007/s10072-022-06158-wCrossRefPubMedPubMedCentral

19.

Ha ET, Antonios JP, Soto H et al (2014) Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol Neuroinflammation 1(2):66–76CrossRef

20.

Killock D (2020) Extent of resection is important across glioblastoma molecular subtypes. Nat Rev Clin Oncol 17(5):275. https://doi.org/10.1038/s41571-020-0344-8CrossRefPubMed

Titel: The effect of indicators of CALLY index on survival in glioblastoma
verfasst von: Umut Ogün Mutlucan
Cihan Bedel
Fatih Selvi
Ökkeş Zortuk
Cezmi Çağrı Türk
Mustafa Korkut
Publikationsdatum: 01.04.2024
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-024-03666-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen